All In Biotech

NDA 021057 · Organon USA Organon

Ganirelix Acetate

Ganirelix Acetate · Injection

NovelPriority review

Last checked: Nov 20, 2026Latest source record: Sep 23, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1999

Jul 29, 1999

Approved uses

1

Original approval plus efficacy supplements

Registered trials

75

16 Phase 3, 4 recruiting

FAERS reports

719

327 serious, 4 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Sep 29, 2026.

INDICATIONS AND USAGE Ganirelix Acetate Injection is indicated for the inhibition of premature LH surges in women undergoing controlled ovarian hyperstimulation.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jul 29, 1999 Original approval · Type 1 - New Molecular Entity · priority review LetterLabelReview
1 products under this application
  • GANIRELIX ACETATE · GANIRELIX ACETATE 250MCG/0.5ML · INJECTABLE, INJECTION · Prescription · TE AP

Clinical trials

Interventional ClinicalTrials.gov studies with "Ganirelix" as an intervention, any sponsor and status, largest first.

All 75 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • ovarian hyperstimulation syndrome225
  • needle issue48
  • ascites44
  • nausea44
  • no adverse event40
  • poor quality device used40
  • headache36
  • injection site pain34
  • drug ineffective31
  • dyspnoea29
  • fatigue29
  • product quality issue28

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20111
20121
201320
201448
20152
20168
20174
201824
201951
202031
202145
2022114
202358
2024101
202568
2026143

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 65 on PubMed

Sponsor: Merck & Co.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.